Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMNN Imunon, Inc.

Closed Good Friday 04-17 16:00:00 EDT

0.8900

+0.0288

+3.34%

盘后0.8510

-0.0390-4.38%

18:45 EDT

High0.8900	Low0.8165	Vol75.91K
Open0.8556	D1 Closing0.8612	Amplitude8.53%
Mkt Cap12.91M	Tradable Cap10.92M	Total Shares14.50M
T/O64.25K	T/O Rate0.62%	Tradable Shares12.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"IMNN","market":"US","secType":"STK","nameCN":"Imunon, Inc.","latestPrice":0.89,"timestamp":1744920000000,"preClose":0.8612,"halted":0,"volume":75910,"hourTrading":{"tag":"盘后","latestPrice":0.851,"preClose":0.89,"latestTime":"18:45 EDT","volume":1040,"amount":889.431,"timestamp":1744929923131},"delay":0,"floatShares":12266345,"shares":14500685,"eps":-1.618003,"marketStatus":"Closed Good Friday","change":0.0288,"latestTime":"04-17 16:00:00 EDT","open":0.8556,"high":0.89,"low":0.8165,"amount":64254.368685999994,"amplitude":0.085346,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.618003,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":959745600000,"exchange":"NASDAQ","adjPreClose":0.8612,"preHourTrading":{"tag":"盘前","latestPrice":0.8612,"preClose":0.8612,"latestTime":"09:00 EDT","volume":4,"amount":3.4448,"timestamp":1744894853237},"postHourTrading":{"tag":"盘后","latestPrice":0.851,"preClose":0.89,"latestTime":"18:45 EDT","volume":1040,"amount":889.431,"timestamp":1744929923131},"volumeRatio":1.40871469163077},"requestUrl":"/m/hq/s/IMNN","defaultTab":"news","newsList":[{"id":"2523840506","title":"IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…","url":"https://stock-news.laohu8.com/highlight/detail?id=2523840506","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523840506?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 22:19","pubTimestamp":1743171540,"startTime":"0","endTime":"0","summary":"On March 24, 2025, Imunon, Inc.  announced it reached alignment with the U.S. FDA on the protocol for a Phase 3 clinical trial, referred to as OVATION 3, of its lead candidate IMNN-001 for the treatment of women with newly diagnosed advanced ovarian cancer. Trial sites are currently being initiated with the first patient to be enrolled in the near term.The following slide provides the overall design of the trial. Eligible patients will have either Stage IIIc and IV advanced ovarian cancer and will be randomized to receive neoadjuvant chemotherapy , interval debulking surgery, and adjuvant chemotherapy. Patients who are positive for homologous recombination deficiency  are also eligible and will receive poly ADP-ribose polymerase  inhibitor therapy as part of standard-of-care  maintenance therapy. The primary endpoint is overall survival , with secondary endpoints evaluating surgical response score, chemotherapy response score, clinical response , and time to second-line treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imnn-protocol-place-phase-3-141900552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMNN","BK4203","BK4139","LU0053671581.USD","BK4161","ITT","SOC","BK4225","ORR","BK4097","GSD","LU0054578231.USD","OS","BK4213","HR"],"gpt_icon":0},{"id":"2522827480","title":"Imunon Price Target Maintained With a $14.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522827480","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522827480?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:48","pubTimestamp":1742986080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 06:48 ET (10:48 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN"],"gpt_icon":0},{"id":"2521773231","title":"Imunon Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2521773231","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521773231?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 22:46","pubTimestamp":1742827560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 10:46 ET (14:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN"],"gpt_icon":0},{"id":"2521747892","title":"Imunon Inc: Currently Initiating Trial Sites and Working With Trial Investigators to Begin Enrolling Study Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747892","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747892?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:00","pubTimestamp":1742817607,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71ED:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2521574785","title":"Imunon Finalizes Phase 3 Study Design With FDA for Imnn-001 in Newly Diagnosed Advanced Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521574785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521574785?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:00","pubTimestamp":1742817607,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2521747447","title":"IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747447","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747447?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047774/0/en/IMUNON-Finalizes-Phase-3-Study-Design-with-FDA-for-IMNN-001-in-Newly-Diagnosed-Advanced-Ovarian-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","ITT","BK4157","LU0149725797.USD","IE00B19Z4B17.USD","LU0971096721.USD","IE00B66KJ199.SGD","LU0053671581.USD","IE00B1BXHZ80.USD","BK4139","BK4097","LU0882574139.USD","BK4006","LU0054578231.USD","BK4161","IMNN","LU1363072403.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0170899867.USD","AEIS","IE0031619046.USD","CMC","IE00BHPRN162.USD","LU0267386448.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2514375360","title":"IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…","url":"https://stock-news.laohu8.com/highlight/detail?id=2514375360","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514375360?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 18:07","pubTimestamp":1740737220,"startTime":"0","endTime":"0","summary":"Imunon, Inc.  is continuing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin -12 expressing plasmid that allows for the durable, local, and targeted expression of IL-12 in the peritoneum. IL-12 is a potent pro-inflammatory cytokine that mediates a number of important cellular processes, including T cell and natural killer cell activation , the production of interferon-gamma , and alteration of myeloid-derived suppressor cells in the tumor microenvironment . While shown to be effective in pre-clinical tumor models, IL-12 therapy initially showed underwhelming results in the clinic along with very high levels of toxicity when administered systemically. This is likely due to the fact that the direct targets of IL-12 are not circulating lymphocytes, but rather immune cells located within the tumor and lymph nodes. Thus, while systemi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imnn-phase-3-ovarian-cancer-100700685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","IE00BHPRN162.USD","IE00BKVL7J92.USD","ITT","LU0054578231.USD","LU1363072403.SGD","OS","CMC","LU0053671581.USD","HR","BK4225","IE00B1BXHZ80.USD","LU0971096721.USD","BK4161","LU0149725797.USD","LU0267386448.USD","BK4113","LU0170899867.USD","CBD","LU0882574139.USD","IE00BZ1G4Q59.USD","BK4139","BK4097","BK4203","IMNN"],"gpt_icon":0},{"id":"2514345750","title":"Q4 2024 Imunon Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2514345750","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514345750?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 17:29","pubTimestamp":1740734951,"startTime":"0","endTime":"0","summary":"Good morning. My name is Mike, and I will be your operator today. At this time, I would like to welcome you to Imunon's full year 2024 financial results conference call.All lines have been placed on mute to prevent any background noise. Following the speaker's prepared remarks, there will be a question and answer session.Please note this event is being recorded. I would now like to turn the call over to Peter Vazho of ICR Healthcare, Investor Relations Representative for Imunon. Please go ahead.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-imunon-inc-earnings-092911553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMNN"],"gpt_icon":0},{"id":"2514157423","title":"Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2514157423","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514157423?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 15:28","pubTimestamp":1740727713,"startTime":"0","endTime":"0","summary":"Cash and Cash Equivalents: $5.9 million as of December 31, 2024.Research and Development Expenses: $11.6 million for 2024, up from $11.3 million in 2023.General and Administrative Expenses: $7.5 million in 2024, down from $9.7 million in 2023.Net Loss: $18.6 million or $1.62 per share for 2024, compared to $19.5 million or $2.16 per share for 2023.Cash Runway: Expected to fund operations late into the second quarter of 2025.GuruFocus has detected 2 Warning Signs with IMNN.For the complete transcript of the earnings call, please refer to the full earnings call transcript.IMNN-001 demonstrated a strong safety profile with no elevation of immune-related adverse events, making it a promising candidate for ovarian cancer treatment.Imunon Inc  is actively pursuing non-dilutive funding and partnerships to support their clinical timelines and strategic objectives.Q: What is your updated strategy in terms of patient population for the phase 3 ovarian cancer study and any other details you can s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imunon-inc-imnn-q4-2024-072833962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMNN"],"gpt_icon":0},{"id":"2514674653","title":"Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2514674653","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514674653?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 10:50","pubTimestamp":1740711028,"startTime":"0","endTime":"0","summary":"Imunon, Inc. (($IMNN)) has held its Q4 earnings call. Read on for the main highlights of the call. Imunon, Inc.’s latest earnings call painted a pi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/imunon-inc-earnings-call-clinical-success-amid-financial-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/imunon-inc-earnings-call-clinical-success-amid-financial-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNN"],"gpt_icon":0},{"id":"2514351013","title":"Imunon Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2514351013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514351013?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 01:57","pubTimestamp":1740679020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2025 12:57 ET (17:57 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN"],"gpt_icon":0},{"id":"2514208387","title":"Imunon Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2514208387","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514208387?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 00:42","pubTimestamp":1740674576,"startTime":"0","endTime":"0","summary":"Imunon Inc reports results for the quarter ended December 31 - Earnings SummaryImunon Inc IMNN.OQ reported a quarterly adjusted loss of 35 cents per share for the quarter ended December 31, higher tha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI2KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN"],"gpt_icon":0},{"id":"2514880441","title":"Imunon FY 2024 GAAP EPS $(1.62) Beats $(1.69) Estimate. Cash And Equivalents $5.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2514880441","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514880441?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:07","pubTimestamp":1740661677,"startTime":"0","endTime":"0","summary":"Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.62) per share which beat the analyst consensus estimate of $(1.69) by 4.14 percent. This is a 25 percent increase over losses of $(2.16) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/44004475/imunon-fy-2024-gaap-eps-1-62-beats-1-69-estimate-cash-and-equivalents-5-9m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Imunon FY 2024 GAAP EPS $(1.62) Beats $(1.69) Estimate. Cash And Equivalents $5.9M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN"],"gpt_icon":0},{"id":"2514596802","title":"IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2514596802","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514596802?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:05","pubTimestamp":1740661500,"startTime":"0","endTime":"0","summary":"IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 20","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033835/0/en/IMUNON-Reports-2024-Financial-Results-and-Provides-Business-Update-Highlighting-Significant-Progress-Towards-the-Initiation-of-a-Pivotal-Phase-3-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","BK4080","CMC","LU0149725797.USD","BK4203","LU2065732104.USD","IE00BKVL7J92.USD","BK4139","HR","SITC","PRGS","BK4195","IMNN","BK4211","BK4006","LU0267386448.USD","IE00BZ1G4Q59.USD","LU0971096721.USD","PFS","LU0882574139.USD","IE00BHPRN162.USD","LU0170899867.USD","BK4231","BK4225","LU1363072403.SGD","OS","BK4097"],"gpt_icon":0},{"id":"2514830530","title":"Imunon announces new analyses of results from Phase 1 trial of IMNN-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2514830530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514830530?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:16","pubTimestamp":1740575779,"startTime":"0","endTime":"0","summary":"IMUNON (IMNN) announced new safety and immunogenicity data from ongoing analyses of results from the Company’s first Phase 1 proof-of-concept clini...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imunon-announces-new-analyses-of-results-from-phase-1-trial-of-imnn-101?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imunon-announces-new-analyses-of-results-from-phase-1-trial-of-imnn-101?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2514837886","title":"Imunon Inc - Imnn-101 Induces 2- to 4-Fold Increase in Nab Titers","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837886?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:05","pubTimestamp":1740575100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nTUA5LPN0H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2514837882","title":"Imunon Inc - Imnn-101 Shows Acceptable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837882","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837882?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:05","pubTimestamp":1740575100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nTUA5LPN0H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2514832002","title":"Imunon Announces New Immunogenicity Data From Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of Covid-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2514832002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514832002?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:05","pubTimestamp":1740575100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nTUA5LPN0H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2514983724","title":"IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983724","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983724?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:05","pubTimestamp":1740575100,"startTime":"0","endTime":"0","summary":"Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine technology IMNN-101 induced 2- to 4-fold increase in neutralizing a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3032895/0/en/IMUNON-Announces-New-Immunogenicity-Data-from-Phase-1-Clinical-Trial-of-Its-DNA-Vaccine-in-Treatment-of-COVID-19.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IMNN","BK4109","BK4548","BK4568","BNTX","DNA","BK4551","BK4535","BK4139","BK4585"],"gpt_icon":0},{"id":"2514809434","title":"Imunon Inc  expected to post a loss of 36 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514809434","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514809434?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:45","pubTimestamp":1740491106,"startTime":"0","endTime":"0","summary":"Imunon Inc  expected to post a loss of36cents a share - Earnings Preview Imunon Inc IMNN.OQ IMNN.O is expected to show no change in quarterly revenue when it reports  results on February 27 for the pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL5N3PG1BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imunon.com","stockEarnings":[{"period":"1week","weight":0.0349},{"period":"1month","weight":0.0229},{"period":"3month","weight":-0.0253},{"period":"6month","weight":-0.0969},{"period":"1year","weight":-0.2193},{"period":"ytd","weight":-0.0632}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.424242,"avgChangeRate":0.08883},{"month":2,"riseRate":0.375,"avgChangeRate":0.031658},{"month":3,"riseRate":0.515152,"avgChangeRate":0.050761},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.046996},{"month":5,"riseRate":0.333333,"avgChangeRate":0.069253},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.032462},{"month":7,"riseRate":0.393939,"avgChangeRate":-0.047127},{"month":8,"riseRate":0.424242,"avgChangeRate":0.013026},{"month":9,"riseRate":0.30303,"avgChangeRate":-0.076521},{"month":10,"riseRate":0.30303,"avgChangeRate":-0.041509},{"month":11,"riseRate":0.30303,"avgChangeRate":-0.021904},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.040384}],"exchange":"NASDAQ","name":"Imunon, Inc.","nameEN":"Imunon, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Imunon, Inc.,IMNN,Imunon, Inc.股票,Imunon, Inc.股票老虎,Imunon, Inc.股票老虎国际,Imunon, Inc.行情,Imunon, Inc.股票行情,Imunon, Inc.股价,Imunon, Inc.股市,Imunon, Inc.股票价格,Imunon, Inc.股票交易,Imunon, Inc.股票购买,Imunon, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction